Frazier Financial Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-4,604
Closed -$468K 857
2025
Q4
$468K Sell
4,604
-267
-5% -$21.4K 0.28% 37
2025
Q3
$266K Buy
4,871
+3,495
+254% +$175K 0.16% 48
2025
Q2
$73.1K Buy
1,376
+147
+12% +$7.47K 0.05% 117
2025
Q1
$53.2K Buy
1,229
+731
+147% +$37K 0.04% 132
2024
Q4
$28K Hold
498
0.02% 204
2024
Q3
$33.9K Sell
498
-871
-64% -$49.2K 0.03% 190
2024
Q2
$57.8K Buy
1,369
+44
+3% +$2.42K 0.05% 130
2024
Q1
$91.5K Buy
1,325
+1,064
+408% +$67.3K 0.08% 107
2023
Q4
$19.3K Buy
+261
New +$17.1K 0.02% 239

Other funds holding EXAS

Frazier Financial Advisors's EXAS Position: Q1 2026 in Review

Frazier Financial Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 4,604 shares — an estimated $468K sold.

Frazier Financial Advisors first reported a position in EXAS in Q4 2023 and held it in 9 quarters. The position peaked at $468K in Q4 2025. 6 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Frazier Financial Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Frazier Financial Advisors sold 4,604 Exact Sciences shares in Q1 2026, an estimated $468K.
  • Frazier Financial Advisors first reported a position in Exact Sciences in Q4 2023 and held it in 9 quarters.
  • Frazier Financial Advisors's Exact Sciences position peaked at $468K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Frazier Financial Advisors's 13F filing for Q1 2026, filed 5 May 2026.